Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women

Cancer Research

Volumn 66, Issue 22, 2006, Pages 11070-11076

  García Piñeres, Alfonso J ^a   Hildesheim, Allan ^b   Herrero, Rolando ^d   Trivett, Matthew ^a   Williams, Marcus ^a   Atmetlla, Ivannia ^d   Ramírez, Margarita ^d   Villegas, Maricela ^d   Schiffman, Mark ^b   Rodríguez, Ana Cecilia ^d   Burk, Robert D ^e   Hildesheim, Mariana ^c   Freer, Enrique ^d   Bonilla, José ^d   Bratti, Concepción ^d   Berzofsky, Jay A ^b   Pinto, Ligia A ^a  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Medical Research Solutions   (United States)

^d UNIVERSIDAD DE COSTA RICA   (Costa Rica)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHYTOHEMAGGLUTININ;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER SCREENING; COHORT ANALYSIS; CONTROLLED STUDY; COSTA RICA; CYTOLOGY; DNA DETERMINATION; FEMALE; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VIROLOGY; VIRUS INFECTION; WART VIRUS;

AGE FACTORS; AGED; ALPHAPAPILLOMAVIRUS; CASE-CONTROL STUDIES; COHORT STUDIES; COSTA RICA; DNA, VIRAL; FEMALE; HUMAN PAPILLOMAVIRUS 11; HUMANS; LYMPHOCYTE ACTIVATION; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; SEXUAL BEHAVIOR;

EID: 33845309478     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2034     Document Type: Article

References (45)

1. IARC Monographs on the evaluation of carcinogenic risks to humans: human papillomaviruses. 2005;90.
2. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8.
3. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
4. Chin-Hong PV, Palefsky JM. Human papillomavirus anogenital disease in HIV-infected individuals. Dermatol Ther 2005;18:67-76.
5. Strickler HD, Palefsky JM, Shah KV, et al. Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst 2003;95:1062-71.
6. Clerici M, Merola M, Ferrario E, et al. Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst 1997;89:245-50.
7. + T-cell immunity against early antigens E2 and E6. Cancer Res 2004;64:5449-55.
8. Kadish AS, Timmins P, Wang Y, et al. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol Biomarkers Prev 2002;11:483-8.
9. Tsukui T, Hildesheim A, Schiffman MH, et al. Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology. Cancer Res 1996;56:3967-74.
10. Hildesheim A, Wang SS. Host and viral genetics and risk of cervical cancer: a review. Virus Res 2002;89:229-40.
11. Kadish AS, Ho GY, Burk RD, et al. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia. J Natl Cancer Inst 1997;89:1285-93.
12. Nakagawa M, Stites DP, Patel S, et al. Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J Infect Dis 2000;182:595-8.
13. Bontkes HJ, de Gruijl TD, van den Muysenberg AJ, et al. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. Int J Cancer 2000;88:92-8.
14. de Gruijl TD, Bontkes HJ, Walboomers JM, et al. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome. J Gen Virol 1999;80:399-408.
15. de Gruijl TD, Bontkes HJ, Walboomers JM, et al. Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: a longitudinal study. Cancer Res 1998;58:1700-6.
16. Jacobs MV, Walboomers JM, Snijders PJ, et al. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer 2000;87:221-7.
17. Matos E, Loria D, Amestoy GM, et al. Prevalence of human papillomavirus infection among women in Concordia, Argentina: a population-based study. Sex Transm Dis 2003;30:593-9.
18. Munoz N, Kato I, Bosch FX et al. Risk factors for HPV DNA detection in middle-aged women. Sex Transm Dis 1996;23:504-10.
19. Thomas JO, Herrero R, Omigbodun AA, et al. Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. Br J Cancer 2004;90:638-45.
20. Baay MF, Smits E, Tjalma WA, et al. Can cervical cancer screening be stopped at 50? The prevalence of HPV in elderly women. Int J Cancer 2004;108:258-61.
21. Lazcano-Ponce E, Herrero R, Munoz N, et al. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer 2001;91:412-20.
22. Molano M, Posso H, Weiderpass E, et al. Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br J Cancer 2002;87:324-33.
23. Pham TH, Nguyen TH, Herrero R, et al. Human papillomavirus infection among women in South and North Vietnam. Int J Cancer 2003;104:213-20.
24. Sellors JW, Karwalajtys TL, Kaczorowski JA, et al. Prevalence of infection with carcinogenic human papillomavirus among older women. CMAJ 2002;167:871-3.
25. Castle PE, Schiffman M, Gravitt PE, et al. Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol 2002;68:417-23.
26. Castle PE, Schiffman M, Herrero R, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005;191:1808-16.
27. Strickler HD, Burk RD, Fazzari M, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 2005;97:577-86.
28. Bisset LR, Lung TL, Kaelin M, Ludwig E, Dubs RW. Reference values for peripheral blood lymphocyte phenotypes applicable to the healthy adult population in Switzerland. Eur J Haematol 2004;72:203-12.
29. Chakravarti B, Abraham GN. Aging and T-cell-mediated immunity. Mech Ageing Dev 1999;108:183-206.
30. Chng WJ, Tan GB, Kuperan P. Establishment of adult peripheral blood lymphocyte subset reference range for an Asian population by single-platform flow cytometry: influence of age, sex, and race and comparison with other published studies. Clin Diagn Lab Immunol 2004;11:168-73.
31. Douziech N, Seres I, Larbi A, et al. Modulation of human lymphocyte proliferative response with aging. Exp Gerontol 2002;37:369-87.
32. Huang H, Patel DD, Manton KG. The immune system in aging: roles of cytokines, T cells and NK cells. Front Biosci 2005;10:192-215.
33. Jentsch-Ullrich K, Koenigsmann M, Mohren M, Franke A. Lymphocyte subsets' reference ranges in an age- and gender-balanced population of 100 healthy adults-A monocentric German study. Clin Immunol 2005;116:192-7.
34. Kam KM, Leung WL, Kwok MY, et al. Lymphocyte subpopulation reference ranges for monitoring human immunodeficiency virus-infected Chinese adults. Clin Diagn Lab Immunol 1996;3:326-30.
35. Lugada ES, Mermin J, Kaharuza F, et al. Population-based hematologic and immunologic reference values for a healthy Ugandan population. Clin Diagn Lab Immunol 2004;11:29-34.
36. Sansoni P, Cossarizza A, Brianti V, et al. Lymphocyte subsets and natural killer cell activity in healthy old people and centenarians. Blood 1993;82:2767-73.
37. Sansoni P, Fagnoni F, Vescovini R, et al. T lymphocyte proliferative capability to defined stimuli and costimulatory CD28 pathway is not impaired in healthy centenarians. Mech Ageing Dev 1997;96:127-36.
38. Santagostino A, Garbaccio G, Pistorio A, et al. An Italian national multicenter study for the definition of reference ranges for normal values of peripheral blood lymphocyte subsets in healthy adults. Haematologica 1999;84:499-504.
39. Song C, Vandewoude M, Stevens W, et al. Alterations in immune functions during normal aging and Alzheimer's disease. Psychiatry Res 1999;85:71-80.
40. Tsegaye A, Messele T, Tilahun T, et al. Immunohematological reference ranges for adult Ethiopians. Clin Diagn Lab Immunol 1999;6:410-4.
41. Herrero R, Castle PE, Schiffman M, et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005;191:1796-807.
42. Herrero R, Schiffman MH, Bratti C, et al. Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. Rev Panam Salud Publica 1997;1:362-75.
43. Bratti MC, Rodriguez AC, Schiffman M, et al. Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10000 women in Guanacaste, Costa Rica. Rev Panam Salud Publica 2004;15:75-89.
44. Eichler H, Beck C, Bernard F, Bugert P, Kluter H. Use of recombinant human deoxyribonuclease (DNase) for processing of a thawed umbilical cord blood transplant in a patient with relapsed acute lymphoblastic leukemia. Ann Hematol 2002;81:170-3.
45. Pinto LA, Trivett MT, Wallace D, et al. Fixation and cryopreservation of whole blood and isolated mononuclear cells: influence of different procedures on lymphocyte subset analysis by flow cytometry. Cytometry B Clin Cytom 2005;63:47-55.